Used in the development of therapies targeting angiogenesis, particularly in oncology. It binds to VEGFR1 (FLT1), inhibiting vascular endothelial growth factor signaling, which plays a key role in tumor blood vessel formation. This antibody has been explored in the context of neutralizing pathological angiogenesis in cancers and other diseases involving abnormal blood vessel growth, such as age-related macular degeneration and diabetic retinopathy. Its high specificity makes it valuable for research and as a reference in biosimilar development and diagnostic assays.